Dr Paul H Sugarbaker

Dr. Paul H. Sugarbaker, MD
Pioneer of Peritoneal Mesothelioma Treatment
Specialty	Surgical Oncology
Key Innovation	Cytoreductive Surgery + HIPEC
Procedure Named	The Sugarbaker Procedure
HIPEC Temperature	42-43°C (107-109°F)
Survival Achieved	2.5 to 7+ years
Standard of Care	Endorsed by PSOGI
Free Case Review →

Executive Summary

Dr. Paul H. Sugarbaker revolutionized the treatment of peritoneal mesothelioma—the form affecting the abdominal lining—by developing cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). His innovation, known as the Sugarbaker procedure, transformed a uniformly fatal diagnosis into one where long-term survival became possible, with some patients living more than seven years. The procedure involves complete visible removal of peritoneal tumors followed by 90 minutes of heated chemotherapy solution (42-43°C) circulated through the abdomen, allowing regional treatment without systemic toxicity. Through decades of research, Dr. Sugarbaker developed three distinct treatment protocols that became the international standard of care, endorsed by the Peritoneal Surface Oncology Group International (PSOGI).

Peritoneal mesothelioma accounts for approximately 10-20% of all mesothelioma cases and develops in the peritoneum, the membrane lining the abdominal cavity. Before Dr. Sugarbaker's innovations, patients with this diagnosis faced a median survival of less than one year with conventional chemotherapy alone. His recognition that heated chemotherapy could penetrate tumor tissue more effectively than systemic treatment led to the development of HIPEC protocols that have since been adopted by specialized cancer centers worldwide.

The three treatment protocols Dr. Sugarbaker developed represent increasingly aggressive approaches based on disease extent and patient condition. Protocol 1 combines cytoreductive surgery with immediate HIPEC; Protocol 2 adds early postoperative intraperitoneal chemotherapy (EPIC) for five days following surgery; Protocol 3 further adds long-term normothermic intraperitoneal chemotherapy (NIPEC) administered through an implanted abdominal port. These graduated approaches allow treatment to be tailored to individual patient needs while maximizing the chance for long-term disease control.

Key Facts

Key Facts: Dr. Paul H. Sugarbaker's Contributions

Key Innovation: Cytoreductive surgery combined with HIPEC for peritoneal mesothelioma Procedure Name: The Sugarbaker Procedure (named in his honor) HIPEC Details: 90 minutes of heated chemotherapy at 42-43°C circulated through the abdomen Survival Range: 2.5 years at low end to more than 7 years at high end Treatment Protocols: Developed three distinct protocols refined over decades Protocol 1: Cytoreductive surgery + immediate HIPEC Protocol 2: Added early postoperative intraperitoneal chemotherapy (EPIC) for 5 days Protocol 3: Further added normothermic intraperitoneal chemotherapy (NIPEC) via abdominal port International Standard: Endorsed by Peritoneal Surface Oncology Group International (PSOGI) Disease Type: Peritoneal mesothelioma (abdominal, not pleural/lung)

Who Is Dr. Paul H. Sugarbaker?

Dr. Paul H. Sugarbaker is a surgical oncologist who dedicated his career to developing treatments for cancers affecting the peritoneum—the lining of the abdominal cavity. While sharing a surname with Dr. David Sugarbaker (the thoracic surgeon who pioneered extrapleural pneumonectomy for pleural mesothelioma), the two physicians are not related and worked independently on different forms of the disease.

Dr. Paul H. Sugarbaker's focus on peritoneal surface malignancies led him to recognize that traditional systemic chemotherapy was largely ineffective for cancers confined to the abdominal cavity. The peritoneum's unique anatomy—a closed space where tumors spread along surfaces rather than through the bloodstream—required a completely different treatment approach.

"Dr. Paul H. Sugarbaker's work gave peritoneal mesothelioma patients something that didn't exist before: a chance at long-term survival. Before HIPEC, this diagnosis was essentially a death sentence. Now we can tell patients about a treatment that has helped some people live seven years or more."

— Paul Danziger, Founding Partner, Danziger & De Llano

What Is the Sugarbaker Procedure?

The Sugarbaker procedure combines two treatment modalities that work synergistically to treat peritoneal mesothelioma:

Cytoreductive Surgery (CRS)

The first component involves surgically removing all visible tumor from the abdominal cavity. This includes:

• Stripping affected peritoneal surfaces
• Removing involved organs or portions of organs when necessary
• Eliminating all macroscopic (visible) disease

The goal is complete cytoreduction—leaving no visible cancer behind. The completeness of cytoreduction is the single most important factor determining patient outcomes.

Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Immediately following cytoreductive surgery, while the patient is still in the operating room, heated chemotherapy solution is circulated throughout the abdominal cavity for 90 minutes.

HIPEC Parameter	Specification
Temperature	42-43°C (107-109°F)
Duration	90 minutes
Delivery	Circulated through open abdomen
Chemotherapy Agents	Varies by protocol (commonly mitomycin C, cisplatin)

✅ Why Heat Matters: The elevated temperature of HIPEC serves multiple purposes. Heat directly kills cancer cells, increases chemotherapy penetration into remaining microscopic disease, and enhances drug effectiveness. The regional delivery allows higher drug concentrations than would be tolerable with IV chemotherapy.

How Did Dr. Sugarbaker Develop His Three Treatment Protocols?

Through decades of research and clinical experience, Dr. Sugarbaker refined his approach, developing three increasingly comprehensive protocols:

Protocol 1: CRS + HIPEC

The foundational approach combines complete cytoreductive surgery with immediate HIPEC during the same operation. This remains the standard starting point for peritoneal mesothelioma treatment.

Protocol 2: CRS + HIPEC + EPIC

Building on Protocol 1, this approach adds Early Postoperative Intraperitoneal Chemotherapy (EPIC) for five days following the initial surgery. Chemotherapy is instilled through drainage catheters left in the abdomen, providing additional treatment to microscopic disease that HIPEC may not have reached.

Protocol 3: CRS + HIPEC + EPIC + NIPEC

The most comprehensive approach further adds Normothermic Intraperitoneal Chemotherapy (NIPEC), delivered through an implanted abdominal port over subsequent months. This provides ongoing regional treatment to prevent recurrence.

"The progression from Protocol 1 to Protocol 3 shows how mesothelioma treatment continues to evolve. Dr. Sugarbaker didn't stop at initial success—he kept refining his approach to help more patients survive longer. That commitment to improvement is exactly what mesothelioma patients need from their medical teams."

— Rod De Llano, Founding Partner, Danziger & De Llano

What Survival Outcomes Has the Sugarbaker Procedure Achieved?

Dr. Sugarbaker's research demonstrated that patients could achieve survival ranging from 2.5 years at the low end to more than 7 years at the high end—a dramatic improvement over the historical prognosis of less than one year for peritoneal mesothelioma.

Factor	Impact on Survival
Completeness of Cytoreduction	Most important factor - complete visible removal essential
Histologic Subtype	Epithelioid tumors respond better than sarcomatoid
Tumor Volume	Lower volume disease has better outcomes
Lymph Node Status	Node-negative patients do better
Treatment Center Experience	High-volume centers achieve better results

ℹ️ Why Peritoneal Has Better Prognosis: Peritoneal mesothelioma generally has better survival outcomes than pleural mesothelioma. The abdominal cavity's anatomy allows for more complete surgical removal, and the disease tends to remain localized longer before spreading to distant sites.

How Did the Sugarbaker Procedure Become the International Standard?

Dr. Sugarbaker's work established cytoreductive surgery with HIPEC as the standard of care for peritoneal mesothelioma, endorsed by the Peritoneal Surface Oncology Group International (PSOGI).

This international recognition came through:

• Rigorous Research: Decades of published studies documenting outcomes
• Protocol Standardization: Clear guidelines for patient selection and treatment delivery
• Training Programs: Education of surgeons worldwide in the technique
• Multi-Center Validation: Confirmation of results at institutions globally
• PSOGI Endorsement: Formal recognition by the leading international organization

The standardization of the Sugarbaker procedure meant that patients could receive consistent, evidence-based treatment regardless of which specialized center they chose.

How Does the Sugarbaker Procedure Differ from Pleural Mesothelioma Treatment?

Peritoneal mesothelioma treatment differs fundamentally from pleural mesothelioma treatment because the diseases behave differently and affect different anatomical spaces:

Aspect	Peritoneal Mesothelioma	Pleural Mesothelioma
Location	Abdominal lining	Lung lining
Standard Surgery	CRS + HIPEC	P/D or EPP
Regional Chemo	HIPEC (heated, intraperitoneal)	Less commonly used
Median Survival	3-5+ years with optimal treatment	18+ months with immunotherapy
Key Surgeon	Dr. Paul H. Sugarbaker	Dr. David Sugarbaker

Where Can Patients Access HIPEC Treatment Today?

The Sugarbaker procedure is now offered at specialized cancer centers throughout the United States. Because of its complexity, HIPEC should only be performed at high-volume centers with experienced surgical teams.

Leading HIPEC Centers Include:

• University of Chicago Medicine
• Memorial Sloan Kettering Cancer Center
• MD Anderson Cancer Center
• Washington Cancer Institute
• Wake Forest Baptist Medical Center

⚠️ Center Selection Matters: Outcomes for HIPEC are significantly better at experienced centers. Patients should seek evaluation at institutions that perform the procedure regularly and have published survival data for peritoneal mesothelioma patients.

"When we help clients with peritoneal mesothelioma, one of our first discussions is about HIPEC and which centers have the most experience. Dr. Sugarbaker's procedure offers real hope, but getting the best outcomes means getting to the right treatment center. We help families navigate these critical decisions."

— David Foster, Client Advocate, Danziger & De Llano

What Is Dr. Paul H. Sugarbaker's Legacy?

Dr. Paul H. Sugarbaker's contributions fundamentally changed the prognosis for peritoneal mesothelioma patients:

Before the Sugarbaker Procedure:

• Peritoneal mesothelioma was uniformly fatal
• Median survival was less than one year
• No standard treatment existed
• Patients received only palliative care

After the Sugarbaker Procedure:

• Long-term survival became possible (5-7+ years)
• International treatment standards were established
• Specialized centers developed worldwide
• Patients have a fighting chance at extended life

His work demonstrates how a single researcher's dedication can transform outcomes for patients with rare diseases.

Get Help Today

If you or a loved one has been diagnosed with peritoneal mesothelioma, accessing specialized treatment—including the HIPEC procedure Dr. Sugarbaker developed—can significantly impact survival. You may also be entitled to compensation from the companies responsible for your asbestos exposure.

The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.

📞 Call (866) 222-9990 or request a free case review online.

See Also

• History of Mesothelioma Research
• Dr. David Sugarbaker (Pleural Mesothelioma Surgeon - Not Related)
• Peritoneal Mesothelioma
• Treatment Options
• Mesothelioma Treatment Centers